SEVERAL FACTORS MAY IMPACT INFLUENZA VACCINE EFFECTIVENESS

Such as:

**ANTIGENIC DRIFT**
Between the time of strain selection and vaccine availability, circulating influenza strains may have the potential to mutate.

**EGG ADAPTATION**
In addition to injecting the WHO-selected seasonal strain into the egg during egg-based manufacturing, a growth-inducing strain is also introduced, which can cause mutations that result in a flu virus that can be different from the intended strain.

For US influenza seasons 2009-2010 through 2018-2019:

A strain mismatch occurred in 7 of these 10 seasons

Almost half of which were caused by egg adaptation in the vaccine strains during manufacturing

**CELL-BASED VACCINE FOR THE PREVENTION OF SEASONAL INFLUENZA**

Implementation of FDA-approved, cell-grown virus seeds eliminates egg-adapted changes that can sometimes occur in the egg-based manufacturing process.

**THE FIRST-AND-ONLY CELL-BASED VACCINE FOR THE PREVENTION OF SEASONAL INFLUENZA IN THE US FOR PEOPLE AGED 4 YEARS AND OLDER**

- As immunogenic as FLUCELVAX TIV for all 4 influenza strains contained in FLUCELVAX QUADRIVALENT.
- Do not administer FLUCELVAX QUADRIVALENT to anyone with a history of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine.

**REIMBURSED THROUGH**

OPT CODES: 90674—SINGLE-DOSE SYRINGE 90756—MULTI-DOSE VIAL

CPT=Current Procedural Terminology

For more information, please see the Important Safety Information below and US full Prescribing Information for FLUCELVAX QUADRIVALENT.
INDICATION and IMPORTANT SAFETY INFORMATION for HCPs

INDICATION AND USAGE
FLUCELVAX® QUADRIVALENT (Influenza Vaccine) is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUCELVAX QUADRIVALENT is approved for use in persons 4 years of age and older. For children and adolescents 4 through 17 years of age, approval is based on the immune response elicited by FLUCELVAX QUADRIVALENT. Data demonstrating a decrease in influenza disease after vaccination of this age group with FLUCELVAX QUADRIVALENT are not available.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
Do not administer FLUCELVAX QUADRIVALENT to anyone with a history of severe allergic reaction e.g. anaphylaxis) to any component of the vaccine.

WARNINGS AND PRECAUTIONS
If Guillain–Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUCELVAX QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

Syncope (fainting) may occur in association with administration of injectable vaccines including FLUCELVAX QUADRIVALENT. Ensure procedures are in place to avoid injury from falling associated with syncope.

After vaccination with FLUCELVAX QUADRIVALENT, immunocompromised individuals, including those receiving immunosuppressive therapy, may have a reduced immune response.

Vaccination with FLUCELVAX QUADRIVALENT may not protect all vaccine recipients against influenza disease.

ADVERSE REACTIONS
The most common (≥10%) local and systemic reactions in children 4 through 5 years of age after first dose of vaccine were tenderness at the injection site (46%), injection site erythema (18%), sleepiness (19%), irritability (16%), injection site induration (13%) and change in eating habits (10%).

The most common (≥10%) local and systemic reactions in children 6 through 8 years of age after first dose of vaccine were pain at the injection site (54%), injection site erythema (22%), injection site induration (16%), headache (14%), fatigue (13%) and myalgia (12%).

The most common (≥10%) local and systemic reactions in children and adolescents 9 through 17 years of age were pain at the injection site (58%), headache (22%), injection site erythema (19%), fatigue (18%) and myalgia (16%), and injection site induration (15%).

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus USA Inc. at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Before administration, please see the full US Prescribing Information for FLUCELVAX QUADRIVALENT.